Announcing a new publication for Acta Materia Medica journal. Cardiovascular diseases (CVDs) pose a significant threat to human health due to the high mortality and morbidity rates. Traditional drugs often have limited efficacy due to inherent constraints, such as low bioavailability and notable side effects. As a highly regarded therapeutic strategy, nanotechnology offers new perspectives and means for treating CVDs.
Nanozyme-based targeted therapeutic drugs specifically address the biological processes in areas affected by CVDs, thereby achieving precise treatment. Compared to traditional drugs, targeted nanozymes offer advantages, such as high efficiency, specificity, controllability, and fewer side effects, showing great efficacy in treating CVDs.
This paper explores the design strategies and mechanisms of nanozyme-based targeted therapy and introduces its application in key CVDs, such as ischemic stroke, myocardial infarction, and coronary heart disease. The challenges of introducing targeted nanozymes into clinical applications and the future development prospects in the treatment of CVDs are also discussed.
Read More: https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0046
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submission Process
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to editorialoffice@amm-journal.org.
Please visit https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal; Facebook (https://www.facebook.com/AMMjournal)
eISSN 2737-7946
Lin Liu, Jie Lv and Xiuxiu Wang et al. Targeted nanozyme-enabled treatment of cardiovascular diseases. Acta Materia Medica. 2025. Vol. 4(1):70-81. DOI: 10.15212/AMM-2024-0046